Hookipa Pharma announces updated HB-200 trial results

Hookipa Pharma announced updated results from its Phase 1/2 clinical trial of HB-200 for the treatment of human papillomavirus 16 positive, or HPV16+, head and neck cancers. The data were published in the company’s abstract for the ASCO 2024 annual meeting and support the company’s pivotal Phase 2/3 trial design for HB-200 in combination with pembrolizumab in the first line setting. The abstract reported data as of January 12 and included 42 patients treated with HB-200 plus pembrolizumab. The treatment was generally well tolerated with a low rate of treatment-related discontinuation and no treatment-related deaths. Among a subpopulation of 17 evaluable patients with CPS of 20 or higher, the updated data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82%. This subpopulation is representative of patients eligible for the company’s pivotal Phase 2/3 trial, which will begin enrolling patients in the fourth quarter of 2024. Additional data will be presented in the Head and Neck Oral Abstract Session at the ASCO. During the presentation, preliminary progression-free survival and overall survival data will be shared for the first time.